-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019
-Neuren retains all rights to trofinetide outside of North America
-Neuren to receive US $10 million upfront plus potential milestones of up to US $455 million and royalties
Ann: Neuren and ACADIA announce agreement for North America, page-3
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.150(0.74%) |
Mkt cap ! $2.566B | |||
| Open | High | Low | Value | Volume |
| $20.40 | $20.50 | $19.88 | $4.961M | 246.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 277 | $20.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.15 | 2400 | 1 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.12 |
Change
-0.150 ( 0.58 %) |
||||
| Open | High | Low | Volume | ||
| $20.45 | $20.50 | $19.88 | 139634 | ||
| Last updated 15.59pm 08/05/2024 ? | |||||
| NEU (ASX) Chart |